宇信科技(300674.SZ):远创基因及光控基因合计减持比例达1%
格隆汇4月3日丨宇信科技(300674.SZ)公布,2020年4月3日,公司收到股东远创基因和光控基因出具的《关于股东减持股份比例达到1%的告知函》。远创基因与光控基因作为同一控制下企业,于2020年2月27日-4月2日期间,通过大宗交易、集中竞价交易方式,合计减持公司股份400.01万股,达到公司股份总数的1.00%。
此次减持后,远创基因仍持有公司股份1688.187万股,占公司总股本的4.23%;光控基因持仍有公司股份815.9928万股,占公司总股本的2.04%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.